Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experienceVincenzo Mazzaferro, Luigi Mariani|Liver Transplantation|2011Cited by 580
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialAndrea Necchi, Roberto Salvioni, Caterina Messina et al.|The Lancet Oncology|2012Cited by 145
Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Cancer|2011Cited by 28
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Blood|2010Cited by 1
[Diet therapy in a case of severe malnutrition due to late-onset celiac disease].M T Duillo, Teresa De Toni, L. Poggi et al.|PubMed|1986Cited by 0